| 新型蛋白酶体抑制剂在多发性骨髓瘤治疗中的应用 |
| |
| 引用本文： | 侯健,李荣. 新型蛋白酶体抑制剂在多发性骨髓瘤治疗中的应用[J]. 中国肿瘤临床, 2018, 45(11): 541-547. DOI: 10.3969/j.issn.1000-8179.2018.11.779 |
| |
| 作者姓名： | 侯健 李荣 |
| |
| 作者单位： | ①.上海交通大学医学院附属仁济医院血液科（上海市 200127） |
| |
| 摘 要： | 多发性骨髓瘤（multiple myeloma，MM）是骨髓浆细胞克隆性增殖的血液系统恶性肿瘤，为血液系统第二常见的恶性肿瘤。蛋白酶体是细胞内的一种复合酶，可以降解泛素标记的蛋白，调节细胞内蛋白水平，在保持细胞内环境的稳定中发挥重要作用。近年来，新型蛋白酶体抑制剂（proteasome inhibitor，PI）的应用使MM的治疗取得了较大的进展，进一步改善了骨髓瘤的治疗疗效。
|
| 关 键 词： | 蛋白酶体抑制剂 多发性骨髓瘤 临床应用 |
| 收稿时间： | 2017-07-13 |
Application of novel proteasome inhibitors in treating multiple myeloma |
| |
| Affiliation: | ①.Department of Hematology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200127, China②.Department of Hematology, Myeloma & Lymphoma Center, Changzheng Hospital of the Second Military Medical University, Shanghai 200003, China |
| |
| Abstract: | Multiple myeloma (MM) is a hematologic malignancy of clonal proliferation of plasma cells, which ranks the second in hematologic malignancy. Proteasome is a complex enzyme in the cell, which can degrade ubiquitin-labeled proteins and regulate intracellular protein levels and play an important role in maintaining the stability of the intracellular environment. In recent years, with the application of new proteasome inhibitors, great progress has been achieved in MM treatment, further improving the therapeutic efficacy of myeloma. |
| |
| Keywords: | |
|
| 点击此处可从《中国肿瘤临床》浏览原始摘要信息 |
|
点击此处可从《中国肿瘤临床》下载免费的PDF全文 |
|
